Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Chuca Marsh who wrote (1282)	8/20/1999 6:02:00 PM
From: Luc Richard	Read Replies (2) \| Respond to of 1501

I have talked with one of my friend who is in internal medicine and he said to me that usually there is no problem with phase 1 clinical trials. the stress comes with phase 2 when they try to prove a positive effect on the sickness, in our case, asthma. I just hope that the sheep model is as good as previously said. And after that, there is phase 3... when we will know for sure the real effect of the medication. In regard with the drug pipeline, maybe it's not necessary to develop a lot of medications if one can do the job for a lot of sickness. Luc Richard